SCHEMBL24650770

SCHEMBL24650770

CC(=O)Nc1cc(C(C)C)c(Cl)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 1/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ GAA P10253 2/20 0.44
▸ JAK2 O60674 1/20 0.42
▸ JAK1 P23458 1/20 0.42
▸ TYK2 P29597 1/20 0.42
▸ CNR2 P34972 3/20 0.39
▸ RORC P51449 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ AAK1 Q2M2I8 1/20 0.38
▸ PIK3C3 Q8NEB9 1/20 0.38
▸ CYP2C19 P33261 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32667078 0.79 L3MBTL1 (0.50) PTK2L3MBTL1GAACYP1A2PIK3C3
SCHEMBL7029088 0.78 PTK2 (0.54) PTK2L3MBTL1GAAJAK2JAK1
SCHEMBL23841368 0.78 NNMT (0.45) TYK2CNR2CYP1A2TSHRMAPK1
Hydrochloric Acid SCHEMBL32667080 0.77 L3MBTL1 (0.49) PTK2L3MBTL1GAACYP1A2PIK3C3
SCHEMBL20031484 0.77 PTK2 (0.53) PTK2L3MBTL1GAAJAK2JAK1
SCHEMBL23610778 0.77 PTK2 (0.53) PTK2L3MBTL1GAAJAK2JAK1
SCHEMBL25118045 0.75 PTK2 (0.51) PTK2L3MBTL1GAAJAK2JAK1
SCHEMBL5318470 0.75 PTK2 (0.51) PTK2L3MBTL1GAAJAK2JAK1
SCHEMBL31493083 0.75 PTK2 (0.54) PTK2L3MBTL1GAAJAK2JAK1
SCHEMBL17606874 0.75 PTK2 (0.54) PTK2L3MBTL1GAAJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11466013-B2 ERK inhibitor and use thereof BETTA PHARMACEUTICALS CO., LTD (CN) 2022-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11466013-B2 ERK inhibitor and use thereof MAPK1, MAPK4, MAPK7 PTK2 48/4885L3MBTL1 2934/4885GAA 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback